{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:13:25Z","timestamp":1793873605064,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s40618-018-0926-9","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T20:41:00Z","timestamp":1532464860000},"page":"345-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Exposure to insulin degludec during pregnancy: report of a small series and review of the literature"],"prefix":"10.1007","volume":"42","author":[{"given":"B. M.","family":"Bonora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. P.","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"issue":"5","key":"926_CR1","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.2337\/dc08-9020","volume":"31","author":"JL Kitzmiller","year":"2008","unstructured":"Kitzmiller JL, Block JM, Brown FM, Catalano PM, Conway DL, Coustan DR, Gunderson EP, Herman WH, Hoffman LD, Inturrisi M, Jovanovic LB, Kjos SI, Knopp RH, Montoro MN, Ogata ES, Paramsothy P, Reader DM, Rosenn BM, Thomas AM, Kirkman MS (2008) Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 31(5):1060\u20131079. \n                    https:\/\/doi.org\/10.2337\/dc08-9020","journal-title":"Diabetes Care"},{"issue":"5","key":"926_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40618-017-0774-z","volume":"41","author":"A Tumminia","year":"2018","unstructured":"Tumminia A, Milluzzo A, Cinti F, Parisi M, Tata F, Frasca F, Frittitta L, Vigneri R, Sciacca L (2018) Abnormal 1-hour post-load glycemia during pregnancy impairs post-partum metabolic status: a single-center experience. J Endocrinol Invest 41(5):567\u2013573. \n                    https:\/\/doi.org\/10.1007\/s40618-017-0774-z","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 1","key":"926_CR3","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.2337\/dc18-S013","volume":"41","author":"AD Association","year":"2018","unstructured":"Association AD (2018) Management of diabetes in pregnancy: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S137\u2013S143. \n                    https:\/\/doi.org\/10.2337\/dc18-s013","journal-title":"Diabetes Care"},{"issue":"2","key":"926_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2337\/diab.46.2.271","volume":"46","author":"Group TDCaCTR","year":"1997","unstructured":"Group TDCaCTR (1997) Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research Group. Diabetes 46(2):271\u2013286","journal-title":"Diabetes"},{"issue":"2","key":"926_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1056\/NEJMra040832","volume":"352","author":"IB Hirsch","year":"2005","unstructured":"Hirsch IB (2005) Insulin analogues. N Engl J Med 352(2):174\u2013183. \n                    https:\/\/doi.org\/10.1056\/NEJMra040832","journal-title":"N Engl J Med"},{"issue":"10","key":"926_CR6","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/dom.12098","volume":"15","author":"K Lambert","year":"2013","unstructured":"Lambert K, Holt RI (2013) The use of insulin analogues in pregnancy. Diabetes Obes Metab 15(10):888\u2013900. \n                    https:\/\/doi.org\/10.1111\/dom.12098","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"926_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ajog.2007.08.005","volume":"198","author":"M Hod","year":"2008","unstructured":"Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H (2008) Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 198(2):186. \n                    https:\/\/doi.org\/10.1016\/j.ajog.2007.08.005","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"926_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc06-1887","volume":"30","author":"ER Mathiesen","year":"2007","unstructured":"Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A (2007) Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 30(4):771\u2013776. \n                    https:\/\/doi.org\/10.2337\/dc06-1887","journal-title":"Diabetes Care"},{"issue":"6","key":"926_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1464-5491.2004.01498.x","volume":"22","author":"JW Wyatt","year":"2005","unstructured":"Wyatt JW, Frias JL, Hoyme HE, Jovanovic L, Kaaja R, Brown F, Garg S, Lee-Parritz A, Seely EW, Kerr L, Mattoo V, Tan M (2005) Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 22(6):803\u2013807. \n                    https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01498.x","journal-title":"Diabet Med"},{"issue":"1","key":"926_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/14767058.2013.799650","volume":"27","author":"M Hod","year":"2014","unstructured":"Hod M, Mathiesen ER, Jovanovic L, McCance DR, Ivanisevic M, Duran-Garcia S, Brondsted L, Nazeri A, Damm P (2014) A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med 27(1):7\u201313. \n                    https:\/\/doi.org\/10.3109\/14767058.2013.799650","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"10","key":"926_CR11","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.2337\/dc11-2264","volume":"35","author":"ER Mathiesen","year":"2012","unstructured":"Mathiesen ER, Hod M, Ivanisevic M, Duran Garcia S, Brondsted L, Jovanovic L, Damm P, McCance DR (2012) Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care 35(10):2012\u20132017. \n                    https:\/\/doi.org\/10.2337\/dc11-2264","journal-title":"Diabetes Care"},{"key":"926_CR12","doi-asserted-by":"publisher","first-page":"649070","DOI":"10.1155\/2012\/649070","volume":"2012","author":"J Lepercq","year":"2012","unstructured":"Lepercq J, Lin J, Hall GC, Wang E, Dain MP, Riddle MC, Home PD (2012) Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int 2012:649070. \n                    https:\/\/doi.org\/10.1155\/2012\/649070","journal-title":"Obstet Gynecol Int"},{"issue":"9","key":"926_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14(9):859\u2013864. \n                    https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01627.x","journal-title":"Diabetes Obes Metab"},{"key":"926_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.04.035","author":"Y Toledano","year":"2018","unstructured":"Toledano Y, Hadar E, Hod M (2018) Pharmacotherapy for hyperglycemia in pregnancy\u2014the new insulins. Diabetes Res Clin Pract. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2018.04.035","journal-title":"Diabetes Res Clin Pract"},{"key":"926_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12721","author":"A Milluzzo","year":"2017","unstructured":"Milluzzo A, Tumminia A, Scalisi NM, Frittitta L, Vigneri R, Sciacca L (2017) Insulin degludec in the first trimester of pregnancy: report of two cases. J Diabetes Investig. \n                    https:\/\/doi.org\/10.1111\/jdi.12721","journal-title":"J Diabetes Investig"},{"key":"926_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1134-y","author":"G Formoso","year":"2018","unstructured":"Formoso G, Ginestra F, Di Dalmazi G, Consoli A (2018) Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. Acta Diabetol. \n                    https:\/\/doi.org\/10.1007\/s00592-018-1134-y","journal-title":"Acta Diabetol"},{"issue":"10","key":"926_CR17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.numecd.2015.06.005","volume":"25","author":"D Russell-Jones","year":"2015","unstructured":"Russell-Jones D, Gall MA, Niemeyer M, Diamant M, Del Prato S (2015) Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 25(10):898\u2013905. \n                    https:\/\/doi.org\/10.1016\/j.numecd.2015.06.005","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0926-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T23:07:14Z","timestamp":1568761634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0926-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0926-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"31 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"GPF received grant support, lecture or advisory board fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Genzyme, Abbott, Novartis and Merck Sharp & Dohme. FD received grants from AstraZeneca, Novo Nordisk and Boehringer-Ingelheim. AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boehringer-Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier and Takeda. BMB declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}